Antje Hoering

10.0k total citations · 1 hit paper
131 papers, 4.4k citations indexed

About

Antje Hoering is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Antje Hoering has authored 131 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 104 papers in Hematology, 64 papers in Molecular Biology and 60 papers in Oncology. Recurrent topics in Antje Hoering's work include Multiple Myeloma Research and Treatments (93 papers), Protein Degradation and Inhibitors (47 papers) and Cancer Treatment and Pharmacology (24 papers). Antje Hoering is often cited by papers focused on Multiple Myeloma Research and Treatments (93 papers), Protein Degradation and Inhibitors (47 papers) and Cancer Treatment and Pharmacology (24 papers). Antje Hoering collaborates with scholars based in United States, United Kingdom and Germany. Antje Hoering's co-authors include Bart Barlogie, John Crowley, Frits van Rhee, Joshua Epstein, Sarah Waheed, Robert Z. Orlowski, John D. Shaughnessy, Rachael Sexton, Brian G.M. Durie and S. Vincent Rajkumar and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Journal of Geophysical Research Atmospheres.

In The Last Decade

Antje Hoering

118 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

2016 594 citations Brian G.M. Durie, Antje Hoering et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Antje Hoering United States	36	3.4k	2.6k	2.1k	595	386	131	4.4k
Janice R. Offord United States	7	2.9k 0.9×	1.9k 0.7×	1.3k 0.6×	986 1.7×	375 1.0×	8	3.8k
Thomas Pabst Switzerland	30	2.5k 0.7×	1.6k 0.6×	1.2k 0.6×	713 1.2×	738 1.9×	180	4.3k
Wim van Putten Netherlands	16	2.1k 0.6×	1.4k 0.5×	603 0.3×	727 1.2×	333 0.9×	26	3.4k
Eytan M. Stein United States	28	2.3k 0.7×	2.0k 0.8×	617 0.3×	636 1.1×	123 0.3×	203	3.4k
Craig B. Reeder United States	34	2.5k 0.7×	2.7k 1.0×	2.3k 1.1×	2.1k 3.5×	2.3k 6.0×	142	5.8k
John Ellerton United States	18	1.4k 0.4×	1.2k 0.5×	1.4k 0.6×	429 0.7×	182 0.5×	29	3.3k
Stephen H. Petersdorf United States	29	2.6k 0.8×	1.2k 0.5×	1.7k 0.8×	769 1.3×	988 2.6×	78	4.7k
Martin Grießhammer Germany	34	2.4k 0.7×	1.6k 0.6×	348 0.2×	3.0k 5.0×	356 0.9×	153	4.1k
Aziz Nazha United States	27	1.6k 0.5×	777 0.3×	288 0.1×	836 1.4×	257 0.7×	170	2.5k
Claude Nicaise United States	20	1.4k 0.4×	537 0.2×	762 0.4×	1.1k 1.8×	224 0.6×	47	2.5k

Countries citing papers authored by Antje Hoering

Since Specialization

Citations

This map shows the geographic impact of Antje Hoering's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antje Hoering with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antje Hoering more than expected).

Fields of papers citing papers by Antje Hoering

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antje Hoering. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antje Hoering. The network helps show where Antje Hoering may publish in the future.

Co-authorship network of co-authors of Antje Hoering

This figure shows the co-authorship network connecting the top 25 collaborators of Antje Hoering. A scholar is included among the top collaborators of Antje Hoering based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antje Hoering. Antje Hoering is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zariffa, Névine, Katherine K. Nishimura, Yu Deng, et al.. (2025). Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapy. Journal for ImmunoTherapy of Cancer. 13(9). e012454–e012454.

Banerjee, Rahul, Rachael Sexton, Aaron S. Rosenberg, et al.. (2024). Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis. Blood. 145(1). 75–84. 3 indexed citations

Cook, Chad, Sunita Yadav, Dinesh Pal Mudaranthakam, et al.. (2024). Title Pending 371. PubMed. 5(1). 1–16. 1 indexed citations

Parker, Terri L., Adam Rosenthal, Vaishali Sanchorawala, et al.. (2024). Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702). Blood. 144(Supplement 1). 3378–3378.

Rhee, Frits van, Adam Rosenthal, Karan Kanhai, et al.. (2022). Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Advances. 6(16). 4773–4781. 17 indexed citations

Usmani, Saad Z., Antje Hoering, Sikander Ailawadhi, et al.. (2020). Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. The Lancet Haematology. 8(1). e45–e54. 80 indexed citations

Schinke, Carolina, Pingping Qu, Syed J. Mehdi, et al.. (2018). The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma. Clinical Cancer Research. 24(12). 2913–2919. 27 indexed citations

Ailawadhi, Sikander, Susanna Jacobus, Rachael Sexton, et al.. (2018). Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer Journal. 8(7). 67–67. 59 indexed citations

Pedersen, Elisabeth A., Rajasree Menon, Kelly M. Bailey, et al.. (2016). Activation of Wnt/β-Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States. Cancer Research. 76(17). 5040–5053. 65 indexed citations

10.

McDonald, James E., Marcus M. Kessler, Amy Buros, et al.. (2016). Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. Clinical Cancer Research. 23(8). 1981–1987. 92 indexed citations

11.

Weinhold, Niels, Christoph Heuck, Adam Rosenthal, et al.. (2015). Clinical value of molecular subtyping multiple myeloma using gene expression profiling. Leukemia. 30(2). 423–430. 47 indexed citations

12.

Papanikolaou, Xanthos, Jackie Szymonifka, Adam Rosenthal, et al.. (2013). Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma. Haematologica. 98(7). 1147–1153. 10 indexed citations

13.

Heuck, Christoph, Jackie Szymonifka, John D. Shaughnessy, et al.. (2012). Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1. Clinical Cancer Research. 18(19). 5499–5506. 13 indexed citations

14.

Usmani, Saad Z., John Crowley, Antje Hoering, et al.. (2012). Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?. Leukemia. 27(1). 226–232. 71 indexed citations

15.

Usmani, Saad Z., Bijay Nair, Pingping Qu, et al.. (2012). Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols. Leukemia. 26(11). 2398–2405. 45 indexed citations

16.

Waheed, Sarah, et al.. (2010). 多発性骨髄腫におけるTotal Therapy 3: 治療の全段階と関連がある,VTD維持成分,ボルテゾミブ,サリドマイド,およびデキサメタゾンの累積用量と早期中断の予後的影響. Blood. 116(8). 1220–1227. 2 indexed citations

17.

Waheed, Sarah, John D. Shaughnessy, Frits van Rhee, et al.. (2010). International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols. Cancer. 117(5). 1001–1009. 22 indexed citations

18.

Durie, Brian G.M., Brian Van Ness, Owen Stephens, et al.. (2009). Genetic polymorphisms of EPHX1, Gsk3β, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma. Leukemia. 23(10). 1913–1919. 10 indexed citations

19.

Haessler, Jeffrey, John D. Shaughnessy, Fenghuang Zhan, et al.. (2007). Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling. Clinical Cancer Research. 13(23). 7073–7079. 75 indexed citations

20.

Hudgens, Michael G., Antje Hoering, & Steven G. Self. (2003). On the analysis of viral load endpoints in HIV vaccine trials. Statistics in Medicine. 22(14). 2281–2298. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact